{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:06:38Z","timestamp":1787695598024,"version":"build-2784847793"},"reference-count":23,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>Brentuximab vedotin (BV) incorporation into frontline chemotherapy regimens improved outcomes for classic Hodgkin lymphoma (cHL). The shared mechanism of action of BV and vinca alkaloids as microtubulin inhibitors increased the potential risk of chemotherapy-induced peripheral neuropathy (CIPN). Rates of CIPN and use of protocol-stipulated dose modifications of a microtubulin inhibitor were examined on the Children\u2019s Oncology Group AHOD1331 study, which compared BV, doxorubicin, vincristine (VCR), etoposide, prednisone, cyclophosphamide (BV-AVE-PC; BV arm) with bleomycin containing doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide (ABVE-PC; standard arm) in patients with high-risk cHL ages 2-21 years.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>AHOD1331 required clinician grading and reporting of \u2265grade 2 CIPN. Protocol-stipulated dose modifications of VCR preceded modification of BV for \u2265grade 2 CIPN in the BV arm, but only required modification of VCR for \u2265grade 3 in the standard arm. Outcomes included CIPN rates, dose modification of microtubulin inhibitors by study arm, clinical factors associated with dose modifications, and event-free survival (EFS) by the presence of dose modification.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>\n              Among the 582 patients who began protocol therapy, 112 developed \u2265grade 2 CIPN. Cumulative incidence of CIPN did not differ by study arm (19.2\n              <jats:italic>v<\/jats:italic>\n              19.8%,\n              <jats:italic>P<\/jats:italic>\n              = .91). CIPN dose modifications occurred more frequently in the BV arm (9.5%\n              <jats:italic>v<\/jats:italic>\n              2.8%,\n              <jats:italic>P<\/jats:italic>\n              = .001); however, most patients with CIPN on the BV arm received full-dose BV. EFS did not differ by the presence of dose modifications after accounting for study arm, age, sex, and stage, although older age was significantly associated with the risk of VCR dose modifications for CIPN.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>A staged dose modification plan for vinca alkaloids and BV as administered in AHOD1331 minimized the effect of incorporating a second microtubulin inhibitor on CIPN without compromising treatment efficacy in the BV arm.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/op.24.00089","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T20:01:14Z","timestamp":1726862474000},"page":"526-534","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":8,"title":["Protocol-Stipulated Dose Modification to Manage Chemotherapy-Induced Peripheral Neuropathy in Children, Adolescents, and Young Adults With High-Risk Hodgkin Lymphoma"],"prefix":"10.1200","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9454-0857","authenticated-orcid":true,"given":"Mallorie B.","family":"Heneghan","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology\/Oncology, University of Utah\/Primary Children's Hospital, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0282-6490","authenticated-orcid":true,"given":"Susan K.","family":"Parsons","sequence":"additional","affiliation":[{"name":"Tufts Medical Center Cancer Center, Boston, MA"},{"name":"Institute for Clinical Research &amp; Health Policy Studies, Tufts Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8919-467X","authenticated-orcid":true,"given":"Frank G.","family":"Keller","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center, Emory University School of Medicine \/ Children's Healthcare of Atlanta, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay A.","family":"Renfro","sequence":"additional","affiliation":[{"name":"University of Southern California and Children's Oncology Group, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglin","family":"Pei","sequence":"additional","affiliation":[{"name":"Children's Oncology Group Statistics &amp; Data Center, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angie Mae","family":"Rodday","sequence":"additional","affiliation":[{"name":"Institute for Clinical Research &amp; Health Policy Studies, Tufts Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8020-2650","authenticated-orcid":true,"given":"Yue","family":"Wu","sequence":"additional","affiliation":[{"name":"Children's Oncology Group Statistics &amp; Data Center, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Punnett","sequence":"additional","affiliation":[{"name":"Division of Haematology\/Oncology, The Hospital for Sick Children, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2260-0395","authenticated-orcid":true,"given":"Jennifer A.","family":"Belsky","sequence":"additional","affiliation":[{"name":"Cancer and Blood Diseases Institute, Riley Hospital for Children\/Indiana University School of Medicine, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9394-6206","authenticated-orcid":true,"given":"Tara O.","family":"Henderson","sequence":"additional","affiliation":[{"name":"Section of Hematology, Oncology, and Stem Cell Transplantation, University of Chicago\/Comer Children's Hospital, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1473-3937","authenticated-orcid":true,"given":"Kara M.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Roswell Park Comprehensive Cancer Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon M.","family":"Castellino","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center, Emory University School of Medicine \/ Children's Healthcare of Atlanta, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_9_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708984"},{"key":"e_1_3_9_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206660"},{"key":"e_1_3_9_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.778"},{"key":"e_1_3_9_5_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21204"},{"key":"e_1_3_9_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70501-1"},{"key":"e_1_3_9_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206125"},{"key":"e_1_3_9_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01399"},{"key":"e_1_3_9_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.2.146"},{"key":"e_1_3_9_10_2","first-page":"438","article-title":"Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis","volume":"88","author":"Landgren O","year":"2003","unstructured":"Landgren O, Algernon C, Axdorph U, et al: Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica 88:438-444, 2003","journal-title":"Haematologica"},{"key":"e_1_3_9_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.12.1776"},{"key":"e_1_3_9_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.4264"},{"key":"e_1_3_9_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010700"},{"key":"e_1_3_9_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/NCC.0b013e318299ad23"},{"key":"e_1_3_9_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-1920-0"},{"key":"e_1_3_9_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7528"},{"key":"e_1_3_9_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03286"},{"key":"e_1_3_9_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009806"},{"key":"e_1_3_9_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1209"},{"key":"e_1_3_9_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.506"},{"key":"e_1_3_9_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/spcare-2021-003506"},{"key":"e_1_3_9_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-167046"},{"key":"e_1_3_9_23_2","unstructured":"Parsons SK Heneghan MB Keller FG et al: The role of protocol-stipulated dose modification in the Children\u2019s Oncology Group AHOD1331 study to manage chemotherapy-induced peripheral neuropathy. Presented at the International Symposium on Childhood Adolescent and Young Adult Hodgkin Lymphoma Memphis TN 2023"},{"key":"e_1_3_9_24_2","volume-title":"COG Data Sharing","year":"2023","unstructured":"COG Data Sharing, 2023. https:\/\/www.childrensoncologygroup.org\/data-sharing#:\u02dc:tex=Consistent%20with%20the%20policies%20of%20the%20National%20Institutes,must%20make%20a%20formal%20request%20to%20the%20Group"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP.24.00089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T21:59:18Z","timestamp":1744408758000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP.24.00089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1200\/OP.24.00089"],"URL":"https:\/\/doi.org\/10.1200\/op.24.00089","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2024-02-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}